Dysmenorrhea Treatment Market : Global Industry Analysis and Opportunity Assessment, 2036

Future Market Insights

Dysmenorrhea Treatment Market

Key Insight

The dysmenorrhea treatment market was valued at USD 7.2 billion in 2025, is projected to reach USD 15.2 billion by 2036 and is forecast to register a 7.1% CAGR between 2026 and 2036. In 2026, non-steroidal anti-inflammatory drugs (NSAIDs) hold 43.0% of treatment type demand and primary dysmenorrhea represents 76.0% of dysmenorrhea type sales.

July 16, 2026

Anurag Sharma

306 Pages

Cite this Report

Dysmenorrhea Treatment Market

https://www.futuremarketinsights.com/reports/dysmenorrhea-treatment-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

Alvogen
Bayer
F. Hoffmann-La Roche Ag
GSK
Mithra Pharmaceuticals
Myovant Sciences
ObsEva SA
The Vanguard Group
Berkshire Hathaway
TherapeuticsMD

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Dysmenorrhea Treatment Market

Key Players

Similar Industry Reports